Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
IOVA Iovance Biotherapeutics, Inc. daily Stock Chart
IOVA [NASD]
Iovance Biotherapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.39 Insider Own0.10% Shs Outstand98.85M Perf Week1.49%
Market Cap1.34B Forward P/E- EPS next Y-1.38 Insider Trans0.00% Shs Float84.44M Perf Month-17.58%
Income-97.90M PEG- EPS next Q-0.31 Inst Own93.00% Short Float5.85% Perf Quarter-20.47%
Sales- P/S- EPS this Y23.80% Inst Trans28.19% Short Ratio5.51 Perf Half Y52.81%
Book/sh3.47 P/B3.92 EPS next Y-8.20% ROA-50.60% Target Price27.14 Perf Year102.99%
Cash/sh- P/C- EPS next 5Y- ROE-53.50% 52W Range4.45 - 19.90 Perf YTD70.00%
Dividend- P/FCF- EPS past 5Y19.40% ROI- 52W High-31.66% Beta5.07
Dividend %- Quick Ratio20.60 Sales past 5Y- Gross Margin- 52W Low205.62% ATR0.82
Employees63 Current Ratio20.60 Sales Q/Q- Oper. Margin- RSI (14)44.80 Volatility4.67% 6.23%
OptionableYes Debt/Eq0.00 EPS Q/Q5.30% Profit Margin- Rel Volume0.98 Prev Close13.15
ShortableYes LT Debt/Eq0.00 EarningsMay 10 AMC Payout- Avg Volume896.04K Price13.60
Recom1.60 SMA20-3.17% SMA50-7.83% SMA20012.31% Volume879,310 Change3.42%
Apr-10-18Upgrade B. Riley FBR, Inc. Neutral → Buy $22
Mar-13-18Reiterated B. Riley FBR, Inc. Neutral $18.50 → $22
Feb-23-18Downgrade B. Riley FBR, Inc. Buy → Neutral $18 → $18.50
Jan-25-18Reiterated H.C. Wainwright Buy $16 → $22
Nov-01-17Reiterated B. Riley FBR, Inc. Buy $17.50 → $18
Jun-15-18 07:09AM  Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar ACCESSWIRE
Jun-14-18 08:39AM  Iovance Biotherapeutics (IOVA) Jumps: Stock Rises 5.1% Zacks
Jun-07-18 08:01AM  Iovance Biotherapeutics Announces First Patient Dosed in Europe for Ongoing C-144-01 Phase 2 Trials in Metastatic Melanoma GlobeNewswire -6.09%
Jun-05-18 11:30AM  Iovance Biotherapeutics Inc (NASDAQ:IOVA): When Will It Breakeven? Simply Wall St.
08:46AM  Implied Volatility Surging for Iovance Biotherapeutics (IOVA) Stock Options Zacks
May-31-18 08:01AM  Iovance Biotherapeutics to Present at Two Investor Conferences in June GlobeNewswire
May-29-18 08:00AM  Report: Exploring Fundamental Drivers Behind ServisFirst Bancshares, Iovance Biotherapeutics, Inc., MarineMax, TriNet Group, Dorian LPG, and AAON New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
May-16-18 10:47AM  4 Small Speculative Names on My Radar TheStreet.com +7.87%
May-15-18 07:10AM  Blog Exposure - RXi Pharma and Iovance Biotherapeutics Announce Research Collaboration ACCESSWIRE
May-14-18 07:10AM  Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks ACCESSWIRE
May-11-18 11:45AM  RXII: Partner Relationships in TILs to Drive Future Value Zacks Small Cap Research
May-10-18 05:13PM  Iovance Biotherapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-03-18 08:01AM  Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018 GlobeNewswire
07:12AM  New HQ puts Tampa immunotherapy company in Moffitts backyard American City Business Journals
May-02-18 08:01AM  Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in May GlobeNewswire
Apr-04-18 07:50AM  Report: Developing Opportunities within Enanta Pharmaceuticals, ServisFirst Bancshares, Lion Biotechnologies, Peapack-Gladstone Financial, Analogic, and Akcea Therapeutics Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-12-18 04:37PM  Iovance Biotherapeutics posts 4Q loss Associated Press
04:01PM  Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
01:15PM  Iovance Biotherapeutics Inc to Host Earnings Call ACCESSWIRE
Mar-08-18 08:01AM  Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Corporate Update on Monday, March 12, 2018 GlobeNewswire
Mar-07-18 08:01AM  Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in March GlobeNewswire
Mar-06-18 06:58PM  Johnson Fistel, LLP Announces Investigations of RH, WageWorks, Inc., BRF S.A., and Iovance Biotherapeutics, Inc.; Investors Encouraged to Contact Firm PR Newswire
Mar-05-18 08:53AM  Is a Surprise Coming for Lion Biotechnologies (IOVA) This Earnings Season? Zacks
Mar-02-18 10:50PM  IOVANCE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. - IOVA PR Newswire
Mar-01-18 08:00AM  Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors GlobeNewswire
Feb-23-18 10:50PM  IOVANCE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. IOVA Business Wire
Feb-14-18 02:00PM  Biotech Heats Up as Fear of Missing Out Returns TheStreet.com
08:00AM  Iovance Biotherapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference GlobeNewswire
Feb-04-18 07:49AM  Iovance Biotherapeutics Inc (NASDAQ:IOVA) And The Healthcare Sector Outlook 2018 Simply Wall St.
Jan-30-18 08:51AM  Iovance Biotherapeutics (IOVA) in Focus: Stock Moves 5.1% Higher Zacks
Jan-29-18 04:01PM  Iovance Biotherapeutics, Inc. Announces Closing of $172.5 Million Common Stock Public Offering GlobeNewswire +5.11%
Jan-25-18 04:33PM  Why W.W. Grainger, Iovance Biotherapeutics, and Dolby Laboratories Jumped Today Motley Fool +27.39%
01:17PM  Here's Why Iovance Biotherapeutics Rose as Much as 29.1% Today Motley Fool
07:45AM  Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock GlobeNewswire
Jan-24-18 04:02PM  Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock GlobeNewswire
04:01PM  Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers GlobeNewswire
Jan-19-18 10:50PM  IOVANCE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. IOVA Business Wire +11.17%
02:32PM  Fledgling Biotech Company's Stock Surges GuruFocus.com
Jan-12-18 10:50PM  IOVANCE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. - IOVA PR Newswire
Jan-10-18 09:20AM  Update in Lawsuit for Investors in Shares of Iovance Biotherapeutics, Inc (NASDAQ: IOVA), formerly Lion Biotechnologies, Inc. Announced by Shareholders Foundation ACCESSWIRE
Jan-05-18 10:50PM  IOVANCE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. IOVA Business Wire
Dec-28-17 03:20PM  Robbins Arroyo LLP: Iovance Biotherapeutics, Inc. (f/k/a Lion Biotechnologies, Inc.) (IOVA) Misled Shareholders According to a Recently Filed Shareholder Derivative Action Business Wire
Dec-15-17 07:40AM  Wired News BioLifes CryoStor(R) Freeze Media and HypoThermosol® Cell Storage Adopted by Iovance Biotherapeutics ACCESSWIRE +11.04%
Dec-13-17 07:00AM  Iovance Biotherapeutics Expands Pipeline of TIL Therapies into Lung Cancer GlobeNewswire
06:30AM  BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics PR Newswire
Dec-07-17 08:00AM  Iovance Biotherapeutics to Webcast Analyst Day on Wednesday, December 13, 2017 GlobeNewswire
Nov-28-17 04:01PM  Iovance Biotherapeutics to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference GlobeNewswire
Nov-13-17 08:00AM  Iovance Biotherapeutics to Present at the Jefferies 2017 London Healthcare Conference GlobeNewswire
Nov-09-17 08:00AM  Iovance Biotherapeutics Announces New LN-144 Phase 2 Clinical Data from Metastatic Melanoma Trial to be Presented at SITC Meeting GlobeNewswire +8.65%
Nov-07-17 08:05AM  Iovance: Earnings Review, Analysts Target Price and Upcoming SITC Data Release ACCESSWIRE
Oct-31-17 04:01PM  Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
09:30AM  Iovance Biotherapeutics Inc to Host Earnings Call ACCESSWIRE
Oct-25-17 08:00AM  Iovance Biotherapeutics to Host Conference Call to Discuss Third Quarter 2017 Financial Results and Provide a Corporate Update on Tuesday, October 31, 2017 GlobeNewswire
Oct-11-17 05:33PM  Iovance Biotherapeutics Announces Six Abstracts to be Presented at the Upcoming 2017 SITC Annual Meeting GlobeNewswire -5.10%
Sep-25-17 04:01PM  Iovance Biotherapeutics, Inc. Announces Closing of $57.5 Million Common Stock Public Offering GlobeNewswire
Sep-20-17 06:07PM  Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $50 Million of Common Stock GlobeNewswire -16.37%
Sep-19-17 04:35PM  Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock GlobeNewswire
Sep-13-17 08:00AM  Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer GlobeNewswire
Sep-11-17 08:00AM  Iovance Biotherapeutics Partners with TrakCel for Personalized Patient Product Management GlobeNewswire
Sep-07-17 08:00AM  Iovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center GlobeNewswire +6.77%
Sep-05-17 08:00AM  Iovance Biotherapeutics to Present at Two Upcoming September Conferences GlobeNewswire +8.33%
Aug-31-17 04:47PM  Iovance Biotherapeutics Announces FDA Fast Track Designation for LN-144 for Treatment of Advanced Melanoma GlobeNewswire
04:27PM  Iovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphoma Indications GlobeNewswire
Aug-16-17 08:00AM  Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer GlobeNewswire -5.32%
Aug-08-17 04:01PM  Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer GlobeNewswire
Aug-01-17 10:48PM  Lion Biotechnologies reports 2Q loss Associated Press
04:01PM  Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Jul-25-17 08:00AM  Iovance Biotherapeutics to Host Conference Call to Discuss Second Quarter 2017 Financial and Operating Results on Tuesday, August 1, 2017 GlobeNewswire
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with PharmaCell B.V and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas M.D. Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
open in yahoo | open in reuters | open in google